Absolutely,
I never posted this original thread. I don't think its a case of MSB vs GILD. Gilead have very much moved their criteria intra and inter-trials. MSB has not. It has consistently set clear criteria for patients in the trials. Gilead has not. They have also changed the end-point. Honestly, just go the Gilead results and read them for yourself. Don't listen to me. Make your own mind up:
https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19
Absolutely,I never posted this original thread. I don't think...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.025(2.29%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.10 | $1.06 | $4.942M | 4.613M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 70659 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 43531 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |